Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3346 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OC
InChI
InChIKey=HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3346 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:58:49 UTC 2023
by
admin
on
Sat Dec 16 17:58:49 UTC 2023
|
Record UNII |
I9ZF7L6G2L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08GA01
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
FDA ORPHAN DRUG |
57991
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
NDF-RT |
N0000000069
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-ATC |
C08GA01
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-VATC |
QC08CA55
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
LIVERTOX |
NBK548324
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
NDF-RT |
N0000007556
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-ATC |
C08CA55
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-ATC |
C08CA05
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-VATC |
QC08CA05
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.2
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
||
|
NDF-RT |
N0000175421
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NIFEDIPINE
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | Description. A yellow, crystalline powder.Solubility. Nifedipine is practically insoluble in water; freely soluble in acetone R; sparingly soluble in dehydrated ethanol R.Category. Cardiovascular drug; calcium-channel blocking agent.Storage. Nifedipine should be kept in a tightly closed container, protected from light.Additional information. CAUTION: Nifedipine decomposes on exposure to daylight, artificial light of certain wavelengths, andultraviolet light.Requirements: Nifedipine contains not less than 98.0% and not more than 102.0% of C17H18N2O6, calculated with reference to the driedsubstance.Note: Throughout the monograph perform the tests and the assay in the dark or under a suitable fluorescent light, using lowactinicglassware. | ||
|
DB01115
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
244-598-3
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
3222
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
DTXSID2025715
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
D009543
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
C29290
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
I9ZF7L6G2L
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
7565
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
m7883
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | Merck Index | ||
|
I9ZF7L6G2L
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
SUB09253MIG
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
7775
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
21829-25-4
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
4485
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
7417
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
2514
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
NIFEDIPINE
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL193
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
757242
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
1922
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
Nifedipine
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
100000090371
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY | |||
|
1463508
Created by
admin on Sat Dec 16 17:58:51 UTC 2023 , Edited by admin on Sat Dec 16 17:58:51 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
DEGRADENT -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
DEGRADENT -> PARENT |
LIGHT INDUCED DEGRADENT
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|